Kalaris Therapeutics annual ebitda
2019
2020
2021
2022
2023
Kalaris Therapeutics EBITDA Growth & History (KLRS)
Kalaris Therapeutics's calculated EBITDA was −$199.5M for fiscal 2023.
View full Kalaris Therapeutics company overviewKalaris Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | −$199.5M | −$29.0M | — |
| 2022 | 2022-12-31 | −$170.5M | −$850,000 | — |
| 2021 | 2021-12-31 | −$169.6M | −$98.4M | — |
| 2020 | 2020-12-31 | −$71.2M | −$44.6M | — |
| 2019 | 2019-12-31 | −$26.7M | — | — |
Kalaris Therapeutics quarterly ebitda
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q4 2023 | 2023-12-31 | −$62.3M | −$21.9M | — |
| Q3 2023 | 2023-09-30 | −$46.9M | −$4.0M | — |
| Q2 2023 | 2023-06-30 | −$47.2M | −$2.7M | — |
| Q1 2023 | 2023-03-31 | −$43.1M | −$418,000 | — |
| Q4 2022 | 2022-12-31 | −$40.3M | $15.4M | — |
| Q3 2022 | 2022-09-30 | −$42.9M | $2.6M | — |
| Q2 2022 | 2022-06-30 | −$44.5M | −$6.9M | — |
| Q1 2022 | 2022-03-31 | −$42.7M | −$11.9M | — |
| Q4 2021 | 2021-12-31 | −$55.7M | −$30.3M | — |
| Q3 2021 | 2021-09-30 | −$45.5M | −$21.6M | — |
| Q2 2021 | 2021-06-30 | −$37.6M | −$25.5M | — |
| Q1 2021 | 2021-03-31 | −$30.8M | −$21.0M | — |
| Q4 2020 | 2020-12-31 | −$25.4M | — | — |
| Q3 2020 | 2020-09-30 | −$23.9M | — | — |
| Q2 2020 | 2020-06-30 | −$12.1M | — | — |
| Q1 2020 | 2020-03-31 | −$9.8M | — | — |
Kalaris Therapeutics ebitda trends
Across the available reported history, Kalaris Therapeutics's ebitda decreased from −$170.5M to −$199.5M, a change of −$29.0M. The latest reported quarter, Q4 2023, shows −$62.3M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kalaris Therapeutics filings at SEC.gov ↗